Side-by-side · Research reference

BronchogenvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/35 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Bronchogen

Tetrapeptide Bioregulator · Khavinson-School

0.05 ng/mLEffective concentrationZakutskiĭ 2006

60 daysCOPD model durationTitova 2017

30 daysTreatment courseKuzubova 2015

Research models: tissue culture / parenteral

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Bronchogen

Vesugen

Primary target

Bronchial epithelial cellsKuzubova 2015

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015 Titova 2017

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

—

Not applicable — does not operate via hormone axis

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Bronchogen

Vesugen

Effective concentration (culture)

0.05 ng/mLZakutskiĭ 2006

Demonstrated in organotypic tissue culture of bronchial explants.

—

Treatment duration (animal)

1 month (30 days)Kuzubova 2015 Titova 2017

Course duration in rat COPD models.

—

Evidence basis

Animal models (rat) / organotypic cultureTitova 2017 Kuzubova 2015 Zakutskiĭ 2006

No human clinical trials reported in available literature.

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Model system

NO₂-induced COPD (60-day intermittent exposure)Titova 2017

—

Tissue specificity

Selective for bronchopulmonary tissue

Part of Khavinson organ-specific bioregulator series.

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

Frequency

—

Not specified in available literature

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

04Side Effects & Safety

Parameter

Bronchogen

Vesugen

Animal safety profile

No adverse effects reported in published rat studies

Limited safety data; only animal models available.

—

Human data

Absent — no clinical trials in humans reported

—

Long-term effects

Unknown — maximum study duration 30 days in animals

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Bronchogen

—

Vesugen

—

Relative Contraindications

Bronchogen

—

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Bronchogen

Vesugen

1. Research context only

Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Animal model protocol

In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017 Kuzubova 2015

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Organotypic culture

Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Khavinson bioregulator tradition

Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

06Stack Synergy

Bronchogen

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)